VintaBio focuses on developing and manufacturing consistent, high-quality viral vectors to alleviate bottlenecks in cell and gene therapy development. The company emerged from stealth with $64 million in funding and a custom-built manufacturing facility in Philadelphia that is open and accepting orders. VintaBio was founded by Junwei Sun and Dr. Shangzhen Zhou, who developed the first viral vectors used for life‑saving therapies, including the cell therapy that cured Emily Whitehead and the first two FDA‑approved gene therapies. Its development and manufacturing team has over a century of experience in the cell and gene therapy space and has played key roles in the development of leading therapies on the market. David Radspinner was appointed CEO at launch, and the company positions itself to address the currently underserved viral vector area of CGT development.

Total raised

$64M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2023